Taho Pharmaceuticals Ltd. (TPEX:6467)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
220.50
-7.00 (-3.08%)
At close: Oct 15, 2026

Taho Pharmaceuticals Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1.988.41-1.076.366.89
Revenue Growth
-74.53%---83.23%-7.71%-44.45%
Gross Profit
1.755.41--0.075.065.67
Operating Income
-242.57-220.14-170.13-121.1-66.71-74.36
Net Income
-238.34-214.4-167.44-120.68-66.3-11.45
Earnings Per Share
-4.58-4.16-3.69-3.12-1.84-0.33
EPS Growth
------

Revenue by Geography

Fiscal YearFY 2025
Period EndingDec '25
Japan
0.08
United State
8.33
Total
8.41

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
299.77389.98495.87229.77106.381.22
Total Debt
8.5711.3116.6521.62-4.92
Net Cash (Debt)
291.2378.66479.22208.15106.376.31
Net Cash Growth
-24.85%-20.98%130.22%95.82%39.30%-40.26%
Net Cash Per Share
5.607.3610.565.372.962.20

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-200.08-203.73-156.91-104.22-62.78-2.96
Capital Expenditures
-4.98-5.41-8.82-2.89-0.83-0.41
Free Cash Flow
-205.05-209.14-165.73-107.1-63.61-3.37
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
88.49%64.29%--6.75%79.52%82.32%
Operating Margin
-12244.62%-2617.59%--11359.94%-1049.20%-1079.46%
Pretax Margin
-12031.45%-2549.32%--11321.11%-1042.75%-166.19%
Profit Margin
-12031.45%-2549.32%--11321.11%-1042.75%-166.19%
FCF Margin
-10351.03%-2486.80%--10047.00%-1000.49%-48.95%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
5793.72681.34-112.8718.9217.47